This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boffito, M.
Right arrow Articles by Shah, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boffito, M.
Right arrow Articles by Shah, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2005, p. 4386-4389, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4386-4389.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate

Marta Boffito,1* Anton Pozniak,1 Brian P. Kearney,2 Christopher Higgs,1 Anita Mathias,2 Lijie Zhong,2 and Jaymin Shah2

PK Research, Chelsea and Westminster Hospital, London, United Kingdom,1 Gilead Sciences, Inc., Foster City, California2

Received 24 March 2005/ Returned for modification 31 May 2005/ Accepted 12 July 2005

A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when coadministered in 29 healthy volunteers. Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUCtau) ratio. No interaction between tenofovir and nelfinavir was observed.

* Corresponding author. Mailing address: PK Research, St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, United Kingdom. Phone: 44 20 8846 6507. Fax: 44 20 8746 5628. E-mail: marta.boffito{at}chelwest.nhs.uk.

Antimicrobial Agents and Chemotherapy, October 2005, p. 4386-4389, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4386-4389.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tong, L., Phan, T. K., Robinson, K. L., Babusis, D., Strab, R., Bhoopathy, S., Hidalgo, I. J., Rhodes, G. R., Ray, A. S. (2007). Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In Vitro. Antimicrob. Agents Chemother. 51: 3498-3504 [Abstract] [Full Text]  
  • Chittick, G. E., Zong, J., Blum, M. R., Sorbel, J. J., Begley, J. A., Adda, N., Kearney, B. P. (2006). Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.. Antimicrob. Agents Chemother. 50: 1304-1310 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»